Investigation of rituximab for candidate of high-risk living-donor renal transplantatio
Not Applicable
- Conditions
- end-stage chronic renal failure
- Registration Number
- JPRN-UMIN000018769
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
There were 59 patients in the rituximab group and 17 in the non-rituximab group. The estimated glomerular filtration rate did not differ significantly between groups until 24 months after transplantation. Cytomegalovirus clinical symptoms , including fever over 38 degree and gastrointestinal symptoms , and the 5-year survival rates of death-censored graft loss did not differ significantly between groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Not provided
Exclusion Criteria
1) excluding 1)-4), 6) (see above) 2) impertinent recipient for this study assessed by main/co-scholar 3) without concensus of recipient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) disappearance of B cell 2) existence of antibody mediated rejection 3) relapse of FSGS 4) effectiveness for rejection 5) effectiveness for relapsing nephropathy
- Secondary Outcome Measures
Name Time Method